BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

260 related articles for article (PubMed ID: 22728006)

  • 1. Relation of carbohydrate antigen-125 to left atrial remodeling and its prognostic usefulness in patients with heart failure and preserved left ventricular ejection fraction in women.
    Hung CL; Hung TC; Liu CC; Wu YJ; Kuo JY; Hou CJ; Yeh HI
    Am J Cardiol; 2012 Oct; 110(7):993-1000. PubMed ID: 22728006
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Usefulness of N-terminal pro-brain natriuretic Peptide and brain natriuretic peptide to predict cardiovascular outcomes in patients with heart failure and preserved left ventricular ejection fraction.
    Grewal J; McKelvie RS; Persson H; Tait P; Carlsson J; Swedberg K; Ostergren J; Lonn E
    Am J Cardiol; 2008 Sep; 102(6):733-7. PubMed ID: 18773998
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Comparison of midregional pro-atrial natriuretic peptide with N-terminal pro-B-type natriuretic peptide in predicting survival in patients with chronic heart failure.
    von Haehling S; Jankowska EA; Morgenthaler NG; Vassanelli C; Zanolla L; Rozentryt P; Filippatos GS; Doehner W; Koehler F; Papassotiriou J; Kremastinos DT; Banasiak W; Struck J; Ponikowski P; Bergmann A; Anker SD
    J Am Coll Cardiol; 2007 Nov; 50(20):1973-80. PubMed ID: 17996563
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Growth differentiation factor-15 is a useful prognostic marker in patients with heart failure with preserved ejection fraction.
    Izumiya Y; Hanatani S; Kimura Y; Takashio S; Yamamoto E; Kusaka H; Tokitsu T; Rokutanda T; Araki S; Tsujita K; Tanaka T; Yamamuro M; Kojima S; Tayama S; Kaikita K; Hokimoto S; Ogawa H
    Can J Cardiol; 2014 Mar; 30(3):338-44. PubMed ID: 24484911
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Differences in biomarkers in patients with heart failure with a reduced vs a preserved left ventricular ejection fraction.
    de Denus S; Lavoie J; Ducharme A; O'Meara E; Racine N; Sirois MG; Neagoe PE; Zhu L; Rouleau JL; White M
    Can J Cardiol; 2012; 28(1):62-8. PubMed ID: 22104539
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Prognostic value of cystatin C on admission in heart failure with preserved ejection fraction.
    Carrasco-Sánchez FJ; Galisteo-Almeda L; Páez-Rubio I; Martínez-Marcos FJ; Camacho-Vázquez C; Ruiz-Frutos C; Pujol-De La Llave E
    J Card Fail; 2011 Jan; 17(1):31-8. PubMed ID: 21187262
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Clinical and prognostic effects of atrial fibrillation in heart failure patients with reduced and preserved left ventricular ejection fraction.
    Linssen GC; Rienstra M; Jaarsma T; Voors AA; van Gelder IC; Hillege HL; van Veldhuisen DJ
    Eur J Heart Fail; 2011 Oct; 13(10):1111-20. PubMed ID: 21642293
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Left atrial remodeling and function in advanced heart failure with preserved or reduced ejection fraction.
    Melenovsky V; Hwang SJ; Redfield MM; Zakeri R; Lin G; Borlaug BA
    Circ Heart Fail; 2015 Mar; 8(2):295-303. PubMed ID: 25593126
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Carbohydrate antigen 125: a useful marker of congestion, fibrosis, and prognosis in heart failure with preserved ejection fraction.
    Menghoum N; Badii MC; Deltombe M; Lejeune S; Roy C; Vancraeynest D; Pasquet A; Gerber BL; Horman S; Gruson D; Beauloye C; Pouleur AC
    ESC Heart Fail; 2024 Jun; 11(3):1493-1505. PubMed ID: 38339764
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Cutoff values of NT-proBNP for the prediction of low functional capacity, decreased ejection fraction and cardiovascular events in patients with heart failure.
    Koç M; Bozkurt A; Yildiray-Sahin D; Unal I; Acartürk E
    Cardiol J; 2009; 16(1):43-9. PubMed ID: 19130415
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Association of a Novel Diagnostic Biomarker, the Plasma Cardiac Bridging Integrator 1 Score, With Heart Failure With Preserved Ejection Fraction and Cardiovascular Hospitalization.
    Nikolova AP; Hitzeman TC; Baum R; Caldaruse AM; Agvanian S; Xie Y; Geft DR; Chang DH; Moriguchi JD; Hage A; Azarbal B; Czer LS; Kittleson MM; Patel JK; Wu AHB; Kobashigawa JA; Hamilton M; Hong T; Shaw RM
    JAMA Cardiol; 2018 Dec; 3(12):1206-1210. PubMed ID: 30383171
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Prognostic value of N-terminal pro C-type natriuretic peptide in heart failure patients with preserved and reduced ejection fraction.
    Lok DJ; Klip IT; Voors AA; Lok SI; Bruggink-André de la Porte PW; Hillege HL; Jaarsma T; van Veldhuisen DJ; van der Meer P
    Eur J Heart Fail; 2014 Sep; 16(9):958-66. PubMed ID: 25082741
    [TBL] [Abstract][Full Text] [Related]  

  • 13. N-terminal proatrial natriuretic peptide and prognosis in patients with heart failure and preserved systolic function.
    Andersson B; Hall C
    J Card Fail; 2000 Sep; 6(3):208-13. PubMed ID: 10997746
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Prevalence of, associations with, and prognostic value of tricuspid annular plane systolic excursion (TAPSE) among out-patients referred for the evaluation of heart failure.
    Damy T; Kallvikbacka-Bennett A; Goode K; Khaleva O; Lewinter C; Hobkirk J; Nikitin NP; Dubois-Randé JL; Hittinger L; Clark AL; Cleland JG
    J Card Fail; 2012 Mar; 18(3):216-25. PubMed ID: 22385942
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Effects of vasodilation in heart failure with preserved or reduced ejection fraction implications of distinct pathophysiologies on response to therapy.
    Schwartzenberg S; Redfield MM; From AM; Sorajja P; Nishimura RA; Borlaug BA
    J Am Coll Cardiol; 2012 Jan; 59(5):442-51. PubMed ID: 22281246
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Differential impact of heart rate and blood pressure on outcome in patients with heart failure with reduced versus preserved left ventricular ejection fraction.
    Maeder MT; Kaye DM
    Int J Cardiol; 2012 Mar; 155(2):249-56. PubMed ID: 21035207
    [TBL] [Abstract][Full Text] [Related]  

  • 17. [Changes in NT-proBNP levels in patients with atrial fibrillation related to heart failure].
    Pokorná V; Jurkovicová O; Kaluzay J; Stecová A; Pont'uch P
    Vnitr Lek; 2010 Aug; 56(8):788-94. PubMed ID: 20845610
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Inflammatory pathways in patients with heart failure and preserved ejection fraction.
    Niethammer M; Sieber M; von Haehling S; Anker SD; Munzel T; Horstick G; Genth-Zotz S
    Int J Cardiol; 2008 Sep; 129(1):111-7. PubMed ID: 17658631
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Plasma amino-terminal pro-brain natriuretic peptide: a novel approach to the diagnosis of cardiac dysfunction.
    Campbell DJ; Mitchelhill KI; Schlicht SM; Booth RJ
    J Card Fail; 2000 Jun; 6(2):130-9. PubMed ID: 10908087
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Cardiovascular features of heart failure with preserved ejection fraction versus nonfailing hypertensive left ventricular hypertrophy in the urban Baltimore community: the role of atrial remodeling/dysfunction.
    Melenovsky V; Borlaug BA; Rosen B; Hay I; Ferruci L; Morell CH; Lakatta EG; Najjar SS; Kass DA
    J Am Coll Cardiol; 2007 Jan; 49(2):198-207. PubMed ID: 17222731
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 13.